Last reviewed · How we verify
Velbe-Bleomycin-Cisplatin
Velbe-Bleomycin-Cisplatin is a Small molecule drug developed by Centre Leon Berard. It is currently in Phase 2 development. Also known as: Desescalation.
Velbe-Bleomycin-Cisplatin is a chemotherapy regimen used to treat various types of cancer, including extra cranial non seminomatous malignant germ cell tumour, lymphoma, peripheral T cell lymphoma, urothelial carcinoma, and bladder cancer. The regimen consists of small molecule drugs, specifically Velbe, bleomycin, and cisplatin, which are administered to target and kill cancer cells.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Velbe-Bleomycin-Cisplatin |
|---|---|
| Also known as | Desescalation |
| Sponsor | Centre Leon Berard |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Prognostic Significance of ctDNA in HL
- A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent (PHASE2)
- Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (PHASE2)
- Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors (PHASE3)
- Combination Chemotherapy With or Without Radiation Therapy and Peripheral Stem Cell Transplant in Treating Children With Hodgkin's Lymphoma (PHASE2)
- Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer (PHASE3)
- Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Velbe-Bleomycin-Cisplatin CI brief — competitive landscape report
- Velbe-Bleomycin-Cisplatin updates RSS · CI watch RSS
- Centre Leon Berard portfolio CI
Frequently asked questions about Velbe-Bleomycin-Cisplatin
What is Velbe-Bleomycin-Cisplatin?
Who makes Velbe-Bleomycin-Cisplatin?
Is Velbe-Bleomycin-Cisplatin also known as anything else?
What development phase is Velbe-Bleomycin-Cisplatin in?
Related
- Manufacturer: Centre Leon Berard — full pipeline
- Also known as: Desescalation
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing